Delayed hospital purchases, sluggish non-rigid medical demand, and other factors dragged down shenzhen mindray bio-medical electronics' Q3 net income by 9.31% | Financial report watch
Due to factors such as delayed hospital procurement, tight hospital construction funds, and sluggish non-rigid medical demand, in the third quarter, Shenzhen Mindray Bio-Medical Electronics' net income decreased by 9.31% year-on-year, while total revenue increased by 1.43% year-on-year. In the second interim profit distribution in 2024, Shenzhen Mindray Bio-Medical Electronics will distribute 16.50 yuan for every 10 shares.
Q3 revenue growth rate dropped to 1%. Can the next approved botox product in China be featured on imeik technology development? | Interpretations
①In the first three quarters, imeik technology development's performance has shown some growth, but the revenue and net income attributable to shareholders have slowed down. ②In order to seek new growth points, imeik technology development's research and development expenses continue to rise, focusing on the layout of weight management drugs, botulinum toxin and other fields.
imeik technology development Q3 revenue increased by 1.10% year-on-year, net income increased by 2.13% | Financial Report Watch
In the first three quarters, the company achieved revenue of approximately 2.376 billion yuan, a year-on-year increase of 9.46%; net income was approximately 1.586 billion yuan, a year-on-year increase of 11.79%. The operational scale of the company is steadily increasing, and the profitability meets market expectations.
Investors further inquired about the progress of the GLP-1 new drug review. Hebei Changshan Biochemical Pharmaceutical responded that the registration inspection has been completed and the approval time cannot be estimated. Directly focus on the earnings
①At today's earnings conference, investors repeatedly inquired about the progress and approval time of the GLP-1 drug Aibonapeptide injection, with management stating that it is unpredictable; ②Management revealed that the on-site verification and registration inspection of Aibonapeptide have been completed, and clinical trials for weight loss indications have not yet been initiated; ③Regarding the decline in performance compared to multiple quarters, management stated that they will speed up going global to restore the profitability of the heparin business.
Long-serving senior executive of lepu medical technology resigns, can the second generation successor stop the decline in performance? | Express announcement
①Tonight, lepu medical technology announced that General Manager Zhang Zhibin and Deputy General Manager Zheng Guorui resigned, and the Chairman's daughter Pu Fei took over as General Manager, with a "sea turtle elite" background; ②Starting from 2023, lepu medical technology's performance has declined for several consecutive quarters, and the market cap has dropped by one quarter compared to its peak period.
The threat of additional tariffs looms high, intco medical technology's stock price drops by 20%, What are the prospects for its North American layout?
①Today, Intco Medical Technology's stock fell 20 centimeters in the intraday trading session. An employee from the securities department of Intco Medical Technology stated, 'This is because the United States announced the impact of increasing tariffs on some Chinese commodities under Section 301.' ②The employee said that the proportion of the U.S. market in the company's revenue is about 35%, which may pose challenges to the company's performance in the short term. However, the overall potential of the U.S. market is still significant, and the company still plans to increase its efforts to expand into the North American market.